MC-Val-Cit-PAB-MMAE
MC-Val-Cit-PAB-MMAE is a precursor of antibody drug conjugate. It contains a thio reactive maleimidocaproyl (MC) group, a protease-sensitive Val-Cit dipeptide, a PABC linker and a MMAE payload. The MMAE is a synthetic antineoplastic agent. It can be attached to a monoclonal antibody (MAB) which directs it toward cancer cells. Please contact us for GMP-grade inquiries.

-
Catalog:
BP-23969
-
Name:
MC-Val-Cit-PAB-MMAE
-
Formula:
C68H105N11O15
-
MW:
1316.7
-
CAS:
646502-53-6
-
Purity:
98%
-
Ships Within:
24 Hours
-
Storage Condition:
-20°C
-
Solubility:
DMSO, DCM, DMF
-
Shipping:
Ambient Temperature
-
Availability:
In Stock
-
NMR:
View
-
SDS:
View
Product Citations
- Esteban C and Veysel K. Synthesis and Enhanced Cellular Uptake In Vitro of Anti-HER2 Multifunctional Gold Nanoparticles. Cancers. 2019 June; 11(6): pp. 870.
https://www.mdpi.com/2072-6694/11/6/870 - Nervig, C. S., Rice, M., Marelli, M., Christie, R. J., & Owen, S. C. (2025). Modular Synthesis of Anti-HER2 Dual-Drug Antibody-Drug Conjugates Demonstrating Improved Toxicity. Bioconjugate Chemistry.
https://pubs.acs.org/doi/abs/10.1021/acs.bioconjchem.4c00398 - Roberts, S. E., Martin, H. L., Al-Qallaf, D., Tang, A. A., Tiede, C., Gaule, T. G., ... & Tomlinson, D. C. (2024). Affimer reagents enable targeted delivery of therapeutic agents and RNA via virus-like particles. Iscience, 27(8).
https://www.cell.com/iscience/fulltext/S2589-0042(24)01686-9